

ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA



# ESO-ESMO-RCE CLINICAL UPDATE ON RARE ADULT SOLID CANCERS

25-27 November 2016  
Milan, Italy

**Chairs:**

P.G. Casali, IT

R.A. Stahel, CH

Held in collaboration with:



Held under the auspices of



## INTRODUCTION

Rare cancers make up as many as one fifth of all new cancer cases. Amongst them, pediatric cancers and rare hematologic neoplasms are often covered by dedicated educational events, while adult solid rare cancers are hardly grouped together and approached as a collective group of neoplasms. Indeed, they account for as many as 15% of all new cancer cases, thus being the main group within rare cancers. This Course is aimed at dealing with them on an annual basis, to provide the community of clinical oncologists specialising in these tumors with a regular update of recent advances in this specific area. The ultimate goal is to strengthen the educational coverage of a group of cancers which may be neglected in spite of their collective incidence.

According to the RARECARE project, which provided a definition and a list of rare cancers, rare adult solid cancers include the following big families of tumors, each of them being therefore covered by a corresponding educational session within this Course:

- Rare skin cancers and non-cutaneous melanoma
- Rare thoracic tumors
- Rare female genital cancers
- Neuroendocrine tumors
- Endocrine gland tumors
- Sarcomas
- Digestive rare cancers
- Rare urological and male genital tumors
- Central nervous system neoplasms
- Head and neck cancers

Any educational effort in the rare cancer area makes little sense if disconnected from a networking environment. Thus, this Course will be first offered to clinical oncologists involved into the existing networks covering rare adult solid cancers, with a special attention to the new European Reference Networks due to be created within the EU.

From the educational point of view, one cannot expect that even experienced clinical oncologists are knowledgeable about all these tumors. For this reason, the European Faculty of this Masterclass is asked to focus on the most recent advances, always trying to put them into the context of state-of-the-art treatment of these tumors, with a special view to ESMO Clinical Practice Guidelines.

## FACULTY *(as of September)*

- S. Bielack**, Klinikum Stuttgart Olgahospital, Stuttgart, DE
- J.Y. Blay**, Centre Léon Bérard, Lyon, FR
- P.G. Casali**, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
- F. de Braud**, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
- F. De Lorenzo**, European Cancer Patient Coalition, Brussels, BE
- A.P. Dei Tos**, Azienda ULSS9, Treviso, IT
- R. Elisei**, Medicina Clinica e Sperimentale, Università di Pisa, IT
- N. Fazio**, European Institute of Oncology, Milan, IT
- S. Ferrari**, Istituti Ortopedici Rizzoli, Bologna, IT
- M. Garassino**, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
- R. Glynn-Jones**, Mount Vernon Hospital, Northwood, Middlesex, UK
- V. Gregoire**, Université Catholique, Louvain, BE
- S. Grisanti**, A.O. Spedali Civili, Brescia, IT
- L. Licitra**, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
- D. Lorusso**, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
- N. Nicolai**, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
- A. Necchi**, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT
- K. Öberg**, University Hospital, Uppsala, SE
- A. Pica**, Proton Therapy Center, Villigen, CH
- G. Pravettoni**, European Institute of Oncology, Milan, IT
- I. Ray-Coquard**, Centre Léon Bérard, Lyon, FR
- S. Rutkowski**, University Medical Center Hamburg-Eppendorf, DE
- M. Seckl**, Hammersmith Campus, London, UK
- C. Simon**, Université de Lausanne, CHUV Lausanne, CH
- R. Soffiatti**, AOJ San Giovanni Battista, Torino, IT
- R.A. Stahel**, Clinic for Oncology, Zurich, CH
- A. Trama**, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT

**FRIDAY, 25 NOVEMBER****INTRODUCTION**

11:00	<b>Welcome from ESO and ESMO</b>	A. Costa, IT R.A. Stahel, CH
11:15	<b>Introduction</b>	P.G. Casali, IT
11:30	<b>The epidemiology of rare cancers</b>	A. Trama, IT
11:45	<b>The pathologic diagnosis in rare cancers</b>	A.P. Dei Tos, IT
12:00	<b>Patient empowerment in rare cancers</b>	G. Pravettoni
12:15	<b>The scenario of rare cancers in the EU</b>	F. De Lorenzo, BE
12:30	<i>Discussion</i>	
13:00	<b>Lunch</b>	

**SESSION 1 RARE THORACIC CANCERS**

14:00	<b>Mesothelioma</b>	R.A. Stahel, CH
14:30	<b>Thymic neoplasms</b>	M. Garassino, IT
15:00	<i>Discussion</i>	
15:30	<b>Coffee break</b>	

**SESSION 2 NEUROENDOCRINE TUMORS**

16:00	<b>Thoracic neuroendocrine tumors</b>	N. Fazio, IT
16:30	<b>Gastroenteropancreatic neuroendocrine tumors</b>	K. Oeberg, SE
17:00	<i>Discussion</i>	

**SESSION 3 ENDOCRINE GLAND TUMORS**

17:30	<b>Thyroid cancer</b>	R. Elisei, IT
18:00	<b>Adrenal cancer</b>	S. Grisanti, IT
18:30	<i>Discussion</i>	

**SATURDAY, 26 NOVEMBER****SESSION 4 RARE FEMALE GENITAL TUMORS**

8:00	<b>Carcinoma of vagina and vulva</b>	D. Lorusso, IT
8:30	<b>Rare ovarian cancers</b>	I. Ray-Coquard, FR
9:00	<b>Trophoblastic tumors</b>	M. Seckl, UK
9:30	<i>Discussion</i>	
10:00	<b>Coffee break</b>	

**SESSION 5 SARCOMAS**

10:30	<b>Adult soft tissue sarcomas</b>	P.G. Casali, IT
11:00	<b>Gastrointestinal stromal tumors (GIST)</b>	J.Y. Blay, FR

11:30	<b>Ewing sarcoma</b>	S. Ferrari, IT
12:00	<b>Osteosarcoma and other bone tumors</b>	S. Bielack, DE
12:30	<i>Discussion</i>	
13:00	<b>Lunch</b>	

#### SESSION 6 RARE UROLOGICAL AND MALE GENITAL TUMORS

14:00	<b>Testicular cancer</b>	N. Nicolai, IT
14:30	<b>Rare urinary cancers</b>	A. Necchi, IT
15:00	<i>Discussion</i>	
15:30	<b>Coffee break</b>	

#### SESSION 7 CENTRAL NERVOUS SYSTEM TUMORS

16:00	<b>Glioma</b>	R. Soffietti, IT
16:30	<b>Medulloblastoma</b>	S. Rutkowski, DE
17:00	<i>Discussion</i>	

#### SESSION 8 RARE SKIN AND NON-CUTANEOUS MELANOMA

17:30	<b>Skin adnexal tumors</b>	L. Licitra, IT
18:00	<b>Uveal and mucosal melanoma</b>	A. Pica, CH
18:30	<i>Discussion</i>	

## SUNDAY, 27 NOVEMBER

#### SESSION 9 HEAD AND NECK CANCERS

8:30	<b>Laryngeal and hypopharyngeal cancer</b>	C. Simon, CH
9:00	<b>Oropharyngeal cancer</b>	V. Gregoire, BE
9:30	<b>Nasopharyngeal cancer</b>	L. Licitra, IT
10:00	<b>Oral cavity cancer</b>	C. Simon, CH
10:30	<b>Salivary glands cancers</b>	L. Licitra, IT
11:00	<i>Discussion</i>	
11:30	<b>Coffee break</b>	

#### SESSION 10 DIGESTIVE RARE CANCERS

12:00	<b>Biliary tumors</b>	F. de Braud, IT
12:30	<b>Anal carcinoma</b>	R. Glynn-Jones, UK
13:00	<i>Discussion</i>	

#### CLOSING REMARKS

13:30	<b>Take home messages</b>	R.A. Stahel, CH
-------	---------------------------	-----------------

## GENERAL INFORMATION

### ORGANISING SECRETARIAT

European School of Oncology  
Rare Tumours Programme  
c/o Fondazione IRCCS Istituto Nazionale dei Tumori  
Via G. Venezian, 1  
20133 Milano - Italy  
Fax +39 0223902531 - [www.eso.net](http://www.eso.net)  
Email: [raretumours@eso.net](mailto:raretumours@eso.net)

### VENUE

Swiss Chamber - Sala Meili  
Via Palestro, 2  
20121 Milano - Italy  
Tel. +39 027632031  
[www.swisschamber.it](http://www.swisschamber.it)

### REGISTRATION

**REGISTER ONLINE AT [WWW.ESO.NET](http://WWW.ESO.NET)**

	Early (by 30 September 2016)	Late (from 1 October 2016)
Registration fee	EUR 200	EUR 250
Club ESO Members	EUR 150	
ESMO Members	EUR 150	

Rates are quoted in Euro and include VAT.  
Registration grants participation in all sessions, coffee breaks and lunches as indicated in the programme.

### TRAVEL GRANTS

Travel grants (registration, 2-night accommodation and travel expenses contribution, up to the total amount of the grant) are made available on a competitive basis thanks to the support of **Rare Cancers Europe**. Priority will be given to younger candidates and low/middle income Countries.

#### Participants coming from:

- **Italy** EUR 650
- **Southern and Western Europe** EUR 850
- **Northern, Central and Eastern Europe** EUR 950
- **Other and overseas** EUR 1150

Applications should be submitted by **30 September 2016** to:  
[raretumours@eso.net](mailto:raretumours@eso.net)  
and include:

- Short curriculum vitae with full affiliation, contact details and date of birth;
- Letter describing motivation for attending.

## **ACCREDITATION**

Application for CME recognition will be submitted to Accreditation Council of Oncology in Europe (ACOE), to the European Accreditation Council for Continuing Medical Education (EACCME) and to the Italian CME accreditation system. EACCME credits are recognised by the American Medical Association towards the Physician's Recognition Award (PRA).

Information on the status of the applications can be obtained from the organising Secretariat.

## **CANCELLATION OF REGISTRATION OR REPLACEMENT**

Cancellation should be notified to ESO in writing. In case of cancellation without replacement, the fee, less handling charges of EUR 80, will be refunded after the event, provided that the cancellation is received by ESO before 25 October. Replacements will be possible till 25 October.

## **BADGE**

The badge is the only official evidence of registration and should be worn at all times during the event.

## **INSURANCE**

The organisers bear no responsibility for untoward events in relation to the participation in the Course. Participants are advised to take out their own personal and travel insurance.

## **OFFICIAL LANGUAGE**

The official language will be English. No translation will be provided.

### **IMPORTANT DEADLINES**

Travel grants: **30 September 2016**

Early registration: **30 September 2016**

Late registration: **from 1 October 2016**

# REGISTRATION FORM

## CLINICAL UPDATE ON RARE ADULT SOLID CANCERS, 25-27 November 2016, Milan, Italy

Please fill in this form in BLOCK CAPITALS and send by the deadline to:

**European School of Oncology** - Via Turati 29 - 20121 Milan - Italy

Fax: +39 02 85464545 - E mail: [raretumours@eso.net](mailto:raretumours@eso.net)

**ONLINE REGISTRATION AT [WWW.ESO.NET](http://WWW.ESO.NET)**

### PARTICIPANT'S DETAILS

Dr.     Prof.     Mrs.     Mr.

Surname Name

Institute

Department

Street

Zip Code Town Country

Phone Fax Mobile

Email

Profession

Specialisation Main field

VAT number (*compulsory for self-employed persons*)

Fiscal code (*Italian residents only*)

**If your invoice details are different to those above, please complete the following section:**

Invoice contact person

Address

Phone email

VAT number (*compulsory for self-employed persons*)

Fiscal Code (*Italian residents only*)

### REGISTRATION FEES:

*Rates are quoted in Euro and include VAT.*

	<b>Early</b> (by 30 September 2016)	<b>Late</b> (from 1 October 2016)
<b>Registration fee</b>	<input type="checkbox"/> EUR 200	<input type="checkbox"/> EUR 250
<b>Club ESO Members</b>	<input type="checkbox"/> EUR 150	<input type="checkbox"/> EUR 250
<b>ESMO Members</b>	<input type="checkbox"/> EUR 150	<input type="checkbox"/> EUR 250

### PAYMENT DETAILS:

**The registration is processed when payment accompanies the form (*credit card details or copy of bank transfer*)**

Visa/Mastercard    Card Number \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_ / \_\_\_\_\_

Expire date \_\_\_\_\_ / \_\_\_\_\_    CV2 code \_\_\_\_\_

Holder's name: \_\_\_\_\_ and signature

**BANK TRANSFER** with no cost to the beneficiary (please provide a copy of the bank transfer):

**Bank:** Banca Popolare di Milano, Agenzia 24 - Milan, Italy

**Account holder:** European School of Oncology

**Number:** No. 16333

**IBAN:** IT96G0558401624 0000000 16333 - **BIC:** BPMIITMMXXX

**Reference:** "Rare Tumours" + participant's name

I authorize the European School of Oncology to use my personal data according to what is specified in Article 13 DLGS 196, available at [www.eso.net](http://www.eso.net) or on request at fax number +39 02 8546 4545.

Signature Date

